Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trial.

Autor:	Xiong Y; Department of Dermatology, Linyi People's Hospital, Linyi, China., Jiang X; Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China., Lai W; Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Gao X; Department of Dermatology, The First Affiliated Hospital of China Medical University, Shenyang, China., You Y; Department of Dermatology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China., Huang Y; Department of Dermatology, Xining First People's Hospital, Xining, China., Li X; Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou, China., Zhang J; Department of Dermatology, Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, China., Tao S; Department of Dermatology, Wuxi Second People's Hospital, Wuxi, China., Chen J; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Zhang W; Department of Dermatology, Shanghai Dermatology Hospital, Shanghai, China., Yu N; Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, China., Xu N; Department of Dermatology, Shanghai Oriental Hospital, Shanghai, China., Liu C; Department of Dermatology, Weinan Central Hospital, Weinan, China., Zeng W; Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China., Lv S; Department of Dermatology, Strategic Support Force Specialty Medical Center (306 Hospital of PLA), Beijing, China., Wang G; Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Oct 24; Vol. 49 (11), pp. 1330-1337.
DOI:	10.1093/ced/llae135
Abstrakt:	Background: Chloasma is a common skin hyperpigmentation condition, with treatment options ranging from topical agents to advanced interventions such as chemical peels and laser therapy. Salicylic acid, including its supramolecular form (SSA), has shown promise in managing chloasma. However, to date, no multicentre randomized controlled trial of SSA for chloasma is available. Objectives: The purpose of this study was to assess the efficacy and safety of 30% SSA combined with 10% niacinamide in treating -chloasma. Methods: This multicentre (n = 15), randomized, double-blind, parallel placebo-controlled trial (Clinical trial registration number: ChiCTR2200065346) enrolled and randomized 300 participants (1 : 1) to either 30% SSA treatment or placebo, with 150 allocated to treatment and 150 to placebo in the full analysis set, and 144 to treatment and 147 to placebo in the per-protocol set. A Visia® Skin Analysis System was used at each visit to assess the degree of improvement in chloasma lesions. The primary endpoint was the effective rate after 16 weeks, assessed using the modified Melasma Area and Severity Index (mMASI) score [(pretreatment score - post-treatment score)/pretreatment score × 100%]. Results: The total mMASI score, overall score on the Griffiths 10-point scale, and Griffiths 10 score for the left and the right sides of the face were significantly lower in the 30% SSA group than in the placebo group (all P < 0.001). One study of drug-related adverse events (AEs) and one study of drug-unrelated AEs were reported in the 30% SSA group. No AE was reported in the placebo group. Conclusions: Among our patients, 30% SSA combined with 10% niacinamide was shown to be effective and safe for treating chloasma. Competing Interests: Conflicts of interest The authors declare no conflicts of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu